Advancing Oncology Research at Flourish
At the close of 2025, Valkyrie Clinical Trials joined the Flourish Research family, expanding our ability to conduct advanced oncology clinical research. By bringing together specialized expertise in complex oncology studies with strong patient access, this next chapter strengthens our commitment to delivering high-quality research and improving outcomes for patients.
Key capabilities include:
- Early-phase oncology expertise, including first-in-human and dose-escalation studies
- Experience in complex oncology trials, including immuno-oncology and novel therapies
- Strong patient access, supported by established referral networks across Southern and Central California
- Specialized safety infrastructure, including advanced monitoring capabilities for high-acuity studies
By combining deep oncology expertise with Flourish’s national scale and centralized infrastructure, the organization offers a differentiated model for executing complex oncology trials efficiently and reliably.
A Shared Commitment to Patients
At the core of this collaboration is a shared commitment to improving access to innovative cancer therapies. “Partnering with Flourish marks an exciting new chapter for Valkyrie as we advance our mission to expand access to the most effective cancer therapies for patients of all backgrounds,” said Dr. David Berz, founder of Valkyrie Clinical Trials.
As part of the Flourish Research network, the Valkyrie team will continue to play a key role in expanding oncology clinical trial capabilities, supporting sponsors across a growing portfolio of complex and early-phase studies.
Together, Flourish and Valkyrie are advancing oncology research, bringing innovative therapies to patients faster while maintaining a strong focus on quality, safety, and patient-centered care.
Our site network is already supporting the next wave of innovative oncology trials. Explore how Flourish can support your upcoming oncology program.